Bristol-Myers Squibb Company is set to gain access to new targets for the development of checkpoint inhibitors against cancer under a licensing deal with Five Prime Therapeutics Inc carrying an upfront payment of $20 million.
A Phase IV study of bosentan has failed to show that the drug significantly prolongs time to first morbidity or mortality in patients with pulmonary arterial hypertension (PAH) already receiving sildenafil. Bosentan (Tracleer) is marketed by Actelion Pharmaceuticals Ltd.
BioInvent International AB, which is developing three antibodies to treat cancer, plans to raise SEK 48.9 million (€5.5 million) with a rights offering on the NASDAQ OMX Exchange in Stockholm. The proceeds will support the company’s ongoing research.
DiaGenic ASA, a specialist in gene expression technology, is raising NOK 50 million (€6 million) with a rights offering on the Oslo Stock Exchange. The offering comprises 100 million new shares priced at NOK 0.50 per share.
Amgen Inc said that its oncolytic virus product, talimogene laherparepvec (TVEC), reduced the size of tumours in patients with metastatic melanoma during a recent Phase 3 trial. The data comes from a retrospective analysis of nearly 4,000 tumour lesions.
The French biotechnology company TxCell SA has signed an option agreement to license its lead cell therapy for inflammatory bowel disease (IBD) to Ferring International Center SA, and simultaneously announced plans to list its shares on Euronext Paris.
Inotrem SA, a French start-up with a new approach for treating sepsis, has raised €18 million in a Series A round, the largest early funding round in Europe so far this year. The company was co-founded in February 2013 by Jean-Jaques Garaud, formerly of Roche.
Galapagos NV of Belgium said it has sold two of its early-stage service companies, BioFocus and Argenta, to Charles River Laboratories International Inc of the US for €134 million. It retains a third service company in Croatia.
The Vectura Group Plc, which develops and sells products for airway-related diseases, has raised £52 million with a primary offering on the London Stock Exchange in connection with its acquisition of Activaero GmbH, a German specialist in vapor delivery devices called nebulisers, for about £108 million.
Circassia Ltd, which is testing a novel immunotherapy for four major allergies, has raised £200 million in an initial public offering on the London Stock Exchange.